Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01015040 · ClinicalTrials.gov registry record · Phase 1

Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers

A Phase 1 study, sponsored by Astellas Pharma.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT01015040 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01015040, a Phase 1 study, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

The objective of the study is to compare the relative bioavailability and pharmacokinetics of solifenacin succinate suspension versus tablet.

Interventions

  • DRUG solifenacin succinate suspension
  • DRUG solifenacin succinate tablet

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2009-09
Est. Completion 2009-11
Phase Phase 1

Sponsor

Astellas Pharma

165 total trials

What the Registry Record Tells You About NCT01015040

The ClinicalTrials.gov registry entry for NCT01015040 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which solifenacin succinate suspension is the first listed.

NCT01015040 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01015040 about?

NCT01015040 is a clinical study titled "Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers". The objective of the study is to compare the relative bioavailability and pharmacokinetics of solifenacin succinate suspension versus tablet.

What is the current status of trial NCT01015040?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-09. Estimated completion is 2009-11.

What interventions are being tested in trial NCT01015040?

The interventions under investigation include: solifenacin succinate suspension (DRUG), solifenacin succinate tablet (DRUG).

Who is sponsoring clinical trial NCT01015040?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.